716 results on '"Fesik, Stephen W."'
Search Results
2. Expanded profiling of WD repeat domain 5 inhibitors reveals actionable strategies for the treatment of hematologic malignancies.
3. Fragment-Based Screen of SARS-CoV‑2 Papain-like Protease (PLpro).
4. Ribosome subunit attrition and activation of the p53–MDM4 axis dominate the response of MLL-rearranged cancer cells to WDR5 WIN site inhibition
5. Author response: Ribosome subunit attrition and activation of the p53–MDM4 axis dominate the response of MLL-rearranged cancer cells to WDR5 WIN site inhibition
6. REPLY TO TRAN ET AL. : Dimeric KRAS protein–protein interaction stabilizers
7. Interaction of the oncoprotein transcription factor MYC with its chromatin cofactor WDR5 is essential for tumor maintenance
8. WD Repeat Domain 5 Inhibitors for Cancer Therapy: Not What You Think
9. Structure-Based Discovery of Potent, Orally Bioavailable Benzoxazepinone-Based WD Repeat Domain 5 Inhibitors
10. Drugging an undruggable pocket on KRAS
11. Ribosome subunit attrition and activation of the p53–MDM4 axis dominate the response of MLL-rearranged cancer cells to WDR5 WIN site inhibition
12. Specificity of Short Interfering RNA Determined through Gene Expression Signatures
13. MYC and MCL1 Cooperatively Promote Chemotherapy-Resistant Breast Cancer Stem Cells via Regulation of Mitochondrial Oxidative Phosphorylation
14. Structure of a Myeloid cell leukemia-1 (Mcl-1) inhibitor bound to drug site 3 of Human Serum Albumin
15. Solution Structure of a Bcl-2 Homolog from Kaposi Sarcoma Virus
16. Solution Structure of the Antiapoptotic Protein bcl-2
17. NMR and Mutagenesis Evidence for an I Domain Allosteric Site That Regulates Lymphocyte Function-Associated Antigen 1 Ligand Binding
18. Solution Structure of the Cytohesin-1 (B2-1) Sec7 Domain and Its Interaction with the GTPase ADP Ribosylation Factor 1
19. Supplementary Figure S4 from Small Molecule–Mediated Activation of RAS Elicits Biphasic Modulation of Phospho-ERK Levels that Are Regulated through Negative Feedback on SOS1
20. Supplementary Table S1 from Small Molecule–Mediated Activation of RAS Elicits Biphasic Modulation of Phospho-ERK Levels that Are Regulated through Negative Feedback on SOS1
21. Supplementary Figures and Table from A Novel MCL1 Inhibitor Combined with Venetoclax Rescues Venetoclax-Resistant Acute Myelogenous Leukemia
22. Data from A Novel MCL1 Inhibitor Combined with Venetoclax Rescues Venetoclax-Resistant Acute Myelogenous Leukemia
23. Data from Small Molecule–Mediated Activation of RAS Elicits Biphasic Modulation of Phospho-ERK Levels that Are Regulated through Negative Feedback on SOS1
24. Supplementary Fig. S1 from ABT-263 and rapamycin act cooperatively to kill lymphoma cells in vitro and in vivo
25. Supplementary Tables 1-2 from Influence of Bcl-2 Family Members on the Cellular Response of Small-Cell Lung Cancer Cell Lines to ABT-737
26. Supplementary Table 1 from A Small-Molecule Inhibitor of Bcl-XL Potentiates the Activity of Cytotoxic Drugs In vitro and In vivo
27. Evidence for a Role for the Phosphotyrosine-Binding Domain of Shc in Interleukin 2 Signaling
28. Structure-based discovery of potent WD repeat domain 5 inhibitors that demonstrate efficacy and safety in preclinical animal models
29. Approach for targeting Ras with small molecules that activate SOS-mediated nucleotide exchange
30. Twenty years on: the impact of fragments on drug discovery
31. Discovery and biological characterization of potent myeloid cell leukemia‐1 inhibitors
32. Discovery of Potent Orally Bioavailable WD Repeat Domain 5 (WDR5) Inhibitors Using a Pharmacophore-Based Optimization
33. Bcl-XL represents a druggable molecular vulnerability during aurora B inhibitor-mediated polyploidization
34. A Chemical Genomics Screen Highlights the Essential Role of Mitochondria in HIF-1 Regulation
35. Panel Discussion : Topic: Extension of Techniques to Larger Molecules
36. Synergistic action of WDR5 and HDM2 inhibitors in SMARCB1-deficient cancer cells
37. A method for the second-site screening of K-Ras in the presence of a covalently attached first-site ligand
38. Structure-based discovery of potent WD repeat domain 5 inhibitors that demonstrate efficacy and safety in preclinical animal models.
39. Fragment-Based Discovery of Small Molecules Bound to T-Cell Immunoglobulin and Mucin Domain-Containing Molecule 3 (TIM-3)
40. Small molecule Mcl-1 inhibitors for the treatment of cancer
41. Solution Structure of the Shc SH2 Domain Complexed with a Tyrosine-Phosphorylated Peptide from the T-Cell Receptor
42. Model for Mammalian Metallothionein Structure
43. NMR Analysis of the Structure and Metal Sequestering Properties of Metallothioneins
44. Fragment-based drug discovery using NMR spectroscopy
45. The Bcl-2 inhibitor ABT-263 enhances the response of multiple chemotherapeutic regimens in hematologic tumors in vivo
46. Discovery and Structure-Based Optimization of Potent and Selective WDR5 Inhibitors Containing a Dihydroisoquinolinone Bicyclic Core
47. Impact of WIN site inhibitor on the WDR5 interactome
48. An inhibitor of Bcl-2 family proteins induces regression of solid tumours
49. Ligand binding to domain-3 of human serum albumin: a chemometric analysis
50. Discovery of aminoglycoside mimetics by NMR-based screening of Escherichia coli A-site RNA
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.